ReviewCureus2026
Mechanisms of Cytokine Modulation and Inflammatory Cascade in Bio-stimulatory Skin Rejuvenation: A Comprehensive Literature Review of Poly-L-Lactic Acid, Calcium Hydroxyapatite, Polycaprolactone, and Poly-D, L-Lactic Acid.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biostimulatory fillers, such as poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), polycaprolactone (PCL), and calcium hydroxyapatite (CaHA), have transformed aesthetics by promoting neocollagenesis through regulated inflammatory and cytokine-driven cascades. Their clinical effectiveness is well-established, but there is a lack of a synthesis of their mechanisms of action. The proposed comprehensive narrative literature review synthesized the contemporary evidence on the cytokine-modulating mechanisms and pathways of inflammatory responses induced by PLLA, PDLLA, PCL, and CaHA. The study design is a narrative literature review, which is performed using a systematic approach based on PRISMA 2020 guidelines. As a comprehensive literature review incorporating heterogeneous and predominantly non-comparative study designs, a formal risk-of-bias assessment using standardized tools was not performed; however, study limitations were considered qualitatively. It matched the identified mechanistic processes with clinical outcomes and safety profiles. The review included 22 clinical studies published from 1stJanuary 2010 to 28th February 2026, comprising randomized controlled trials, cohort studies, and quasi-experimental designs. Extracted data were systematically categorized into six predefined domains: acute inflammatory profile, macrophage polarization, fibroblast extracellular matrix (ECM) response, angiogenesis, clinical outcomes, and adverse events based on thematic analysis of study endpoints. All four biostimulators elicit a controlled inflammatory response characterized by macrophage infiltration and, in some cases, foreign-body giant cell formation. PLLA and PDLLA promote a transition from pro-inflammatory to pro-regenerative M2 macrophage phenotypes, driving sustained upregulation of Type I and III collagen, elastin, and angiogenesis. PCL induces durable neocollagenesis lasting up to 24 months, supported by neovascularization. CaHA stimulates fibroblast activity and ECM production, with a more pronounced early inflammatory gene signature than PLLA. Clinically, all biostimulators achieve significant and sustained improvements in wrinkle severity, skin quality, and volume restoration, with high patient satisfaction rates. Adverse events were predominantly mild and transient, with nodule formation being most notable with PLLA (4.7-28.6%). The study concluded that PLLA, PDLLA, PCL, and CaHA each elicit distinct yet overlapping inflammatory and cytokine-mediated cascades that culminate in robust neocollagenesis and tissue remodeling. Understanding these mechanistic differences enables clinicians to tailor treatment selection and protocols to achieve optimal, durable aesthetic outcomes with favorable safety profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.